FENC
NASDAQFennec Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks72+100%
2026-03-012026-08-23
Mix3090d
- Insider23(77%)
- SEC Filings3(10%)
- Other2(7%)
- Earnings2(7%)
Latest news
25 items- SECSEC Form 10-Q filed by Fennec Pharmaceuticals Inc.10-Q - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
- PRFennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update~ 2026 Second Quarter Net Product Sales of $17.1 Million, Up 78% Year over Year ~ ~ 2026 Second Quarter Non-GAAP Adjusted EBITDA of $2.8 Million ~ ~ Record PEDMARK® Demand Carried into Third Quarter 2026 as Field Sales Expansion Efforts Continue to Validate Commercial Growth Strategy ~ ~ Real-World Evidence Presented at ASCO 2026 Reinforced that PEDMARK® Can Be Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today rep
- PRFennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2026 financial results before the opening of the U.S. financial markets on Tuesday, August 11, 2026. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: Date: Tuesday, August 11, 2026Time: 8:30 a.m. Eastern TimeWebcast Link: https://edge.media-server.com/mmc/p/tjdvggzn Participant Link: https://register-conf.media-server.com/register/BI48fe753d5b224919a74621f21
- INSIDERFormer Director Raykov Rosty sold $95,800 worth of shares (10,000 units at $9.58) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 131,633 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Medical Officer Sayad Pierre Sargis was granted 168 shares, increasing direct ownership by 0.79% to 21,351 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Strategy Officer Cioffi Christiana Marie was granted 156 shares, increasing direct ownership by 0.64% to 24,488 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Executive Officer Hackman Jeffrey S. was granted 1,159 shares, increasing direct ownership by 2% to 65,143 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Commercial Officer Evans Terry L was granted 168 shares, increasing direct ownership by 0.79% to 21,351 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Andrade Robert was granted 1,703 shares, increasing direct ownership by 0.59% to 292,675 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERFormer Director Raykov Rosty was granted 2,778 shares, increasing direct ownership by 2% to 141,633 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERFormer Director Raykov Rosty sold $99,926 worth of shares (9,599 units at $10.41) as part of a pre-agreed trading plan, was granted 2,778 shares and exercised 15,597 shares at a strike of $2.45, increasing direct ownership by 7% to 138,855 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Commercial Officer Evans Terry L was granted 168 shares, increasing direct ownership by 0.80% to 21,183 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Medical Officer Sayad Pierre Sargis was granted 168 shares, increasing direct ownership by 0.80% to 21,183 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Executive Officer Hackman Jeffrey S. was granted 1,159 shares, increasing direct ownership by 2% to 63,984 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Andrade Robert was granted 1,703 shares, increasing direct ownership by 0.59% to 290,972 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERChief Strategy Officer Cioffi Christiana Marie was granted 156 shares, increasing direct ownership by 0.65% to 24,332 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- PRFennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards ("ISOs") to purchase an aggregate of 10,000 of the Company's common shares to one new non-executive employee of the Company with a grant date of June 15, 2026 under the Company's 2026 Equity Inducement Plan (the "Inducement Plan"). The ISOs were granted as inducements material to the employee entering into employment with the Company in accordance with Nasdaq L
- SECSEC Form S-8 filed by Fennec Pharmaceuticals Inc.S-8 - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
- INSIDERSEC Form 4 filed by Director Brughera Marco Maria4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERSEC Form 4 filed by Director Cook Jodi A4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERSEC Form 4 filed by Director Islam Khalid4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- INSIDERSEC Form 4 filed by Director Rallis Chris A4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
- SECFennec Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
- PRFennec Announces Results of Annual MeetingRESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the "Company") (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025. Detailed results of the vote for the election of directors are set out below: Name of NomineeVotes For% Votes ForVotes Withheld% Votes WithheldDr. Khalid Islam13,858,13197.84%304,7602.15%Mr. Chris A. Rallis13,808,79297.49%354,0992.50%Mr. Marco Brughera13,807,50197.49%355,3902.50%Dr. Jodi Cook13,259,89493.62%902,9976.37%Mr. Jeff Hackman13,4
- INSIDERDirector Raykov Rosty was granted 2,778 shares, exercised 15,597 shares at a strike of $2.45 and sold $93,766 worth of shares (9,747 units at $9.62) as part of a pre-agreed trading plan, increasing direct ownership by 7% to 130,079 units (SEC Form 4)4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
FENC FAQ
6 questionsWhat does Fennec Pharmaceuticals Inc. do?
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.Where does FENC stock trade?
Fennec Pharmaceuticals Inc. (FENC) is listed on NASDAQ.What sector and industry is FENC in?
Fennec Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about FENC?
Fennec Pharmaceuticals Inc. has had 5 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy with a $1600.00 price target on 2026-02-12. Recent price targets range from $1100.00 to $1600.00.What companies are similar to FENC?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare FENC side-by-side with any of them on Quantisnow.How can I track FENC on Quantisnow?
Quantisnow aggregates Fennec Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FENC to receive live email and push alerts on every new disclosure.